medigraphic.com
ISSN 1561-302X (Print)

2014, Number 4

<< Back Next >>

Rev cubana med 2014; 53 (4)

Identification of the primary tumor in patients with metastases presenting as cancer

Senra ALA, Menéndez PR

Language: Spanish
References: 43
Page: 402-416
PDF size: 199.04 Kb.


ABSTRACT

Introduction: today cancer competes with ischemic heart disease as the leading cause of death in Cuba, even far above cerebrovascular disease, accidents, and pneumonia. In many cases, cancer has metastasized and only the primary tumor is only identified in a part of them, while in the rest, the tumor remains "hidden" behind a research considered as "optimal".
Objective: to determine, in our context, how often a primary tumor is identified when the cancer has metastasized, the topographical distribution of metastasis sites and histological variants in cases of "hidden" primary.
Methods: A cross-sectional, prospective and descriptive study was conducted in the Department of Internal Medicine, at Hermanos Ameijeiras Clinical Hospital from January 2010 to January 2013. The working universe consisted of 100 patients with metastasis with no primary tumor identified as diagnosis of hospitalization, who met the inclusion criteria. Location of primary tumor, metastatic sites and histological types were variables used. Descriptive statistics were mainly used, especially those applicable to qualitative variables (incidence).
Results: primary tumor was identified in 50 patients. The most common sites were lung (11 %), colon, ovarian and prostate (5 % each). no primary tumor was identified in 50 % of cases. The most common site of metastasis was liver (56.0 %), followed by lymph (41.0 %) lung and pleura (19.0). the most common strain was well-differentiated adenocarcinoma (42 %) in those patients whose primary tumor failed to be identified; followed by the poorly differentiated carcinoma (34 %) and neuroendocrine carcinoma (20 %).
Conclusions: In our context, identifying the primary tumor is achieved in half of the patients with metastases. This is independent of the number of metastases at presentation. Liver is the most common site of metastasis. The predominant histological variant among patients with "hidden" primary was adenocarcinoma.


REFERENCES

  1. Oncología y Hematología. Cap. 95. En: HarrisonꞋs. Principios de Medicina Interna. 17a ed. Parte VI. Sección 1. Philadelphia: The McGraw-Hill Companies; 2008. p. 614-6.

  2. Hammar S. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol. 2008;29:1393-402.

  3. Abbott NJ, Ronnback L, Hansson E: Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41–53.

  4. Yu Q, Stamenkovic I. Transforming growth factor beta facilitates breast carcinoma metastasis by promoting tumor cell survival. Clin Exp Metastasis. 2004;21:235-42.

  5. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10:169-80.

  6. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.

  7. Muir C. Cancer of unknown primary site. Cancer. 2005;75:353.

  8. Perry Michael. Citing a hypothesis advanced by Larry Norton of the Memorial- Sloan Kettering Cancer Center. The Lancet Oncology. 2010.

  9. Greco F, Hainsworth J. Cancer of unknown primary site. En: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of Oncology. 7a ed. Philadelphia: J.B. Lippincott; 2005. p. 2213-34.

  10. Abbruzzese J, Abbruzzese M, Hess K, Raber M, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 2004;12:1272-80.

  11. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer. 2006;57:120.

  12. Greco F, Vaughan W, Hainsworth J. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104:547-53.

  13. Maiche AG. Cancer of unknown primary. A retrospective study based on 109 patients. Am J Clin Oncol. 1993;16:26-9.

  14. Senra L, Hernández E, Álvarez R, Rodríguez H, Cand C, Roca V. Valor del examen post mortem en pacientes con cáncer de tumor primario oculto. Rev Cubana Med. 2011;50(4):376-89.

  15. Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20 year retrospective data from a tertiary care censer. Ann Diagnos Pathol. 2005;9:77-80.

  16. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS. 2003;111:1089-94.

  17. Pentheroudakis G, Briasoulis E, Pavdilis N. Cancer of unknown primary site: missing primary or missing biology? The Oncologist. 2007;12:418-25.

  18. Ayoub J, Hubbard P, Lenzi. Unknown primary carcinomas: diagnosis and management. En: Pazdur R, editor. Medical oncology. A comprehensive review. 2nd ed. New York: PRR Inc.; 1996. p. 559-66.

  19. ESMO. Minimum clinical recommendations for diagnosis, treatment and followup of. Ann Oncol. 2013;12:1057-8.

  20. NCCN. Practice guidelines in oncology. Occult primary. Version 1. National Comprehensive Cancer Network. Inc.; 2013.

  21. Hillen HFP: Unknown primary tumours. Postgrad Med J. 2006;76:690-3.

  22. Van der Wouw AJ, Jansen RLH. The Unknown biology of the unknown pimary tumour. Annals of Oncology. 2003;14:191-6.

  23. Varadhachary GR, Greco A. Overview of management and future directions in unknown primary carcinoma. Seminars in Oncology. 2009;36(1):75-80.

  24. Losa Gaspà F, Germà JR, Llucha L, Camacho Cuarterob L, Niubó Danielc R, Albareda Boledac JM, et al. Planteamiento diagnóstico y terapéutico frente al cáncer de presentación metastásica y origen desconocido; Rev Clin Esp. 2002;202(11):604-14.

  25. Khosravi P, Rueda A, Álvarez J. Neoplasias de origen desconocido. An Med Inter. 2004;21(10):501-6.

  26. Bishop JF, Tracey E, Glass P, Jelfs , Roder D. Prognosis of sub-types of cancer of unknown primary (CUP) compared to metastasic cancer. J Clin Oncol. 2007;25(18S):abstr 21010.

  27. Chorost MI, Lee C, Yeoh C, Molina M, Ghosh BC. Unknown primary. Journal of Surgical Oncology. 2004;87:191-203.

  28. Leong SP, Cady B, Jablons DM. Clinical patterns of metastasis. Cancer Metast Rev. 2006;25:221-32.

  29. Erlander MG, Moore MW, Cottem P. Molecular classification of carcinoma of unknown primary by gene tissues. J Clin Oncol. 2004;22(14S):abstr 9545.

  30. Mackay B, Ordóñez N. Pathological evaluation of neoplasms with unknown primary tumor site. Semin Oncol. 2003;20:206-28.

  31. Gown A, Vogel A. Monoclonal antibodies to human intermediate filament proteins. Analysis of tumors. Am J Clin Pathol. 1995;84:413-24.

  32. Park JS, Yim JJ, Kang WJ, Chung JK, Yoo ChG, Kim YW. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Research Notes. 2011;4:56.

  33. Karapolat I, Kumanlioğlu K. Impact of FDG-PET/CT for the detection of unknown primary tumours in patients with cervical lymph node metastases. Mol Imag Radionucl Ther. 2012;21:63-8.

  34. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and metaanalysis. EurRadiol. 2009;19:731-44.

  35. Krämer A, Hübner G, Schneeweiss A, Folprecht G, Nebene K. Carcinoma of unknown primary – an orphan disease? Breast Care.2008;3:164-70.

  36. Hwang JE, Yoon JY, Bae WK, Shim HJ, Chung IJ. Complete biologic response to taxane based chemotherapy confirmed by [18F] FDG PET/CT and surgery in a cancer of unknown primary site. J Gynecol Oncol. 2011;23:65-8.

  37. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G, on behalf of the ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Supplement 6): vi64-vi68.

  38. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, et al. Immunohistochemical profile for unknown primary adenocarcinoma. PloS ONE. 2012;7:e31181.

  39. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of diagnostic algorithm. Clin Cancer Res. 2005;11:3766-72.

  40. Briasoulis E, Pavlidis N. Cancer of unknown primary origin. The Oncologist. 2007;2:142-52.

  41. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber AN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 2004;12:1272-80.

  42. Khosravi Shahi P, Del Castillo Rueda A, De Portugal Álvarez J. Neoplasias de origen desconocido. Anales de medicina Interna. 2004;21:501-6.

  43. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548-54.




2020     |     www.medigraphic.com